Patent · US Active

Prevention and treatment of complement-associated eye conditions

US8497094B2 · kind B2 · utility

2Cited by

11References

9Claims

0Family size

Assignee

Genentech, Inc. · US

Inventors

Philip E. Hass · Moss Beach, US
Yin Jianping · Foster City, US
Kenneth Katschke · Fairfield, US
Micah Steffek · San Francisco, US
Christian Wiesmann · Brisbane, US
Menno Van Lookeren Campagne · San Francisco, US

Key dates

Filing date	Jul 20, 2012
Grant date	Jul 30, 2013
Priority date	—
Expiry date	Jul 20, 2032

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY10S435/975
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.